HME04

HME04 is a potent, selective, and orally bioavailable heterobifunctional EP300 degrader developed by Hanmi Pharmaceutical. It utilizes the targeted protein degradation (TPD) platform to selectively target EP300 (p300) for degradation via the ubiquitin-proteasome system (UPS) while sparing the closely related CBP (CREB-binding protein). This selectivity is designed to exploit synthetic lethality in cancers where CBP is deficient or where tumor survival is dependent on EP300. Preclinical studies have demonstrated robust anti-tumor efficacy in EP300-dependent and CBP-deficient cell lines, such as VCaP, and in vivo xenograft models.